4,4'-difluoro-3'-[8-fluoro-7-(1-hydroxy-1-methylethyl)imidazo[1,2-a]pyridin-3-yl]biphenyl-2-carbonitrile

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4,4'-difluoro-3'-[8-fluoro-7-(1-hydroxy-1-methylethyl)imidazo[1,2-a]pyridin-3-yl]biphenyl-2-carbonitrile
• 英文别名: 4,4'-Difluoro-3'-[8-fluoro-7-(1-hydroxy-1-methylethyl)imidazo[1,2-alpha]pyridin-3-yl]biphenyl-2-carbonitrile；5-fluoro-2-[4-fluoro-3-[8-fluoro-7-(2-hydroxypropan-2-yl)imidazo[1,2-a]pyridin-3-yl]phenyl]benzonitrile
• 化学式: C₂₃H₁₆F₃N₃O
• 分子量: 407.395
• InChiKey: VLFITPUZJCLTFQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  61.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-(8-氟咪唑并[1,2-a]吡啶-7-基)丙烷-2-醇 、 3'-Bromo-4,4'-difluorobiphenyl-2-carbonitrile 以to give 4,4′-difluoro-3′-[8-fluoro-7-(1-hydroxy-1-methylethyl)imidazo[1,2-α]pyridin-3-yl]biphenyl-2-carbonitrile (trifluoroacetate salt) as an off-white solid (23 mg, 6%)的产率得到4,4'-difluoro-3'-[8-fluoro-7-(1-hydroxy-1-methylethyl)imidazo[1,2-a]pyridin-3-yl]biphenyl-2-carbonitrile
  参考文献：
  名称：

  Imidazo-pyridine derivatives as ligands for GABA receptors

  摘要：

  一类8-氟-3-苯基咪唑[1,2-α]吡啶衍生物，苯环的间位被一个可选择取代的芳基或杂环基团或一个吡咯烷基取代，该基团通过氧原子或者-NH-或-OCH2-链直接连接或桥接，是GABAA受体的选择性配体，特别是对其中的α2和/或α3和/或α5亚单位具有高亲和力。因此，这些化合物有益于治疗和/或预防中枢神经系统的不良病症，包括焦虑、惊厥和认知障碍。

  公开号：

  US07279580B2

文献信息

• [EN] IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS<br/>[FR] DERIVES D'IMIDAZO-PYRIDINE UTILISES EN TANT QUE LIGANDS POUR LES RECEPTEURS GABA
  申请人：MERCK SHARP & DOHME

  公开号：WO2003099816A1

  公开（公告）日：2003-12-04

  A class of 8-fluoro-3-phenylimidazo[1,2-a]pyridine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group, or by a pyrrolidinonyl group, which is directly attached or bridged by an oxygen atom or by a -NH- or -OCH2- linkage, being selective ligands for GABAA receptors, in particular having high affinity for the α2 and/or α3 and/or α5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.

  一类8-氟-3-苯基咪唑并[1,2-a]吡啶衍生物，通过苯环的间位被一个可选择取代的芳基或杂环芳基团，或者通过一个吡咯烷基团取代，该吡咯烷基团直接连接或通过氧原子或-NH-或-OCH2-键连接，作为GABAA受体的选择性配体，特别是对其α2和/或α3和/或α5亚基具有高亲和力，因此在治疗和/或预防中枢神经系统的不良状况，包括焦虑、惊厥和认知障碍方面具有益处。
• Imidazo-pyridine derivatives as ligands for gaba receptors
  申请人：Goodacre Charles Simon

  公开号：US20050165048A1

  公开（公告）日：2005-07-28

  A class of 8-fluoro-3-phenylimidazo[1,2-a]pyridine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group, or by a pyrrolidinonyl group, which is directly attached or bridged by an oxygen atom or by a —NH— or —OCH 2 — linkage, being selective ligands for GABA A receptors, in particular having high affinity for the α2 and/or α3 and/or α5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.

  一类8-氟-3-苯基咪唑[1,2-a]吡啶衍生物，取代苯环的间位的芳基或杂环基或吡咯烷基，可以是可选的取代基，或是直接通过氧原子或- NH-或-OCH2-连接桥接，是GABAA受体的选择性配体，特别是具有对其α2和/或α3和/或α5亚基高亲和力，因此有益于治疗和/或预防中枢神经系统的不良症状，包括焦虑，抽搐和认知障碍。
• IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS
  申请人：MERCK SHARP & DOHME LTD.

  公开号：EP1511747A1

  公开（公告）日：2005-03-09
• METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME
  申请人：President and Fellows of Harvard College

  公开号：EP3468545A1

  公开（公告）日：2019-04-17
• [EN] METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR RÉDUIRE LE DYSFONCTIONNEMENT TACTILE ET L'ANXIÉTÉ ASSOCIÉS AU TROUBLE DU SPECTRE DE L'AUTISME, AU SYNDROME DE RETT ET AU SYNDROME DE L'X FRAGILE
  申请人：HARVARD COLLEGE

  公开号：WO2017214442A1

  公开（公告）日：2017-12-14

  The present invention features a method of reducing tactile dysfunction or anxiety in a subject diagnosed with Autism Spectrum Disorder, Rett Syndrome, or Fragile X syndrome by administering a GABAA agent having reduced blood brain barrier or by expressing a nucleic acid encoding an exogenous alpha or beta subunit of a GABAA receptor in dorsal root ganglion neurons in the subject using a vector.